Are We missing out the role of oxytocin in overactive bladder syndrome?

References

• Abrams P, Andersson KE, Apostolidis A, et al. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol Urodyn. 2018;37:2271–2272.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Kuzina I, et al. Socioeconomic status and health-related quality of life among adults and older with overactive bladder. Int J Qual Health Care 2018. DOI:10.1093/intqhc/mzy163
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Kuzina I, et al. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male. 2017;20:39–44.
   PubMed Web of Science ®Google Scholar
• Henningsohn L, Kilany S, Svensson M, et al. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an alpha-blocker in men with overactive bladder in Sweden: a non-interventional study. Aging Male. 2017;20:266–276.
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766.
   PubMed Web of Science ®Google Scholar
• Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6:S565–S573.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Loparev S, Ivanovskaya M, et al. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin. Aging Male. 2015;18:44–48.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Goldfischer ER, Steers WD, et al. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male. 2010;13:100–107.
   PubMed Web of Science ®Google Scholar
• Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent). 2007;20:307–314.
   PubMedGoogle Scholar
• Woodford HJ. Anticholinergic drugs for overactive bladder in frail older patients: the case against. Drugs Aging. 2018;35:773–776.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010;106:506–514.
   PubMed Web of Science ®Google Scholar
• Sand PK, Rovner ES, Watanabe JH, et al. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011;28:151–160.
   PubMed Web of Science ®Google Scholar
• Baskaran C, Plessow F, Silva L, et al. Oxytocin secretion is pulsatile in men and is related to social-emotional functioning. Psychoneuroendocrinology. 2017;85:28–34.
   PubMed Web of Science ®Google Scholar
• Herbert Z, Botticher G, Aschoff A, et al. Changing caveolin-1 and oxytocin receptor distribution in the ageing human prostate. Anatom Histol Embryol. 2007;36:361–365.
   PubMed Web of Science ®Google Scholar
• Kimura T, Saji F, Nishimori K, et al. Molecular regulation of the oxytocin receptor in peripheral organs. J Mol Endocrinol. 2003;30:109–115.
   PubMed Web of Science ®Google Scholar
• Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629–683.
   PubMed Web of Science ®Google Scholar
• Cyranowski JM, Hofkens TL, Frank E, et al. Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom Med. 2008;70:967–975.
   PubMed Web of Science ®Google Scholar
• Fliers E, De Vries GJ, Swaab DF. Changes with aging in the vasopressin and oxytocin innervation of the rat brain. Brain Res. 1985;348:1–8.
   PubMed Web of Science ®Google Scholar
• Fuchs AR, Romero R, Keefe D, et al. Oxytocin secretion and human parturition: pulse frequency and duration increase during spontaneous labor in women. Am J Obstet Gynecol. 1991;165:1515–1523.
   PubMed Web of Science ®Google Scholar
• Ogawa S. Physiological variation of oxytocin in normal females and males: relation of estrogen, progesterone, testosterone and LH-RH to oxytocin secretion. Folia Endocrinologica Japonica. 1980;56:1182–1199.
   Google Scholar
• Ivell R, Richter D. The gene for the hypothalamic peptide hormone oxytocin is highly expressed in the bovine corpus luteum: biosynthesis, structure and sequence analysis. EMBO J. 1984;3:2351–2354.
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Dohanics J. Vasopressin and oxytocin secretion in chronically hyposmolar rats. Am J Physiol. 1991;261:R1028–R1038.
   PubMedGoogle Scholar
• Amico JA, Finn FM, Haldar J. Oxytocin and vasopressin are present in human and rat pancreas. Am J Med Sci. 1988;296:303–307.
   PubMed Web of Science ®Google Scholar
• Ivell R, Balvers M, Rust W, et al. Oxytocin and male reproductive function. Adv Exp Med Biol. 1997;424:253–264.
   PubMed Web of Science ®Google Scholar
• Bodanszky M, Sharaf H, Roy JB, et al. Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol. 1992;216:311–313.
   PubMed Web of Science ®Google Scholar
• Romine MT, Anderson GF. Evidence for oxytocin receptors in the urinary bladder of the rabbit. Can J Physiol Pharmacol. 1985;63:287–291.
   PubMed Web of Science ®Google Scholar
• Pandita RK, Nylen A, Andersson KE. Oxytocin-induced stimulation and inhibition of bladder activity in normal, conscious rats-influence of nitric oxide synthase inhibition. Neuroscience. 1998;85:1113–1119.
   PubMed Web of Science ®Google Scholar
• Black LV, Ness TJ, Robbins MT. Effects of oxytocin and prolactin on stress-induced bladder hypersensitivity in female rats. J Pain. 2009;10:1065–1072.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Morelli A, et al. Regulation of epididymal contractility during semen emission, the first part of the ejaculatory process: a role for estrogen. J Sex Med. 2008;5:2010–2016.
   PubMed Web of Science ®Google Scholar
• Nicholson HD, Jenkin L. Oxytocin and prostatic function. Adv Exp Med Biol. 1995;395:529–538.
   PubMedGoogle Scholar
• Sakakibara R, Kishi M, Ogawa E, et al. Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsons Dis. 2011;2011:924605.
   PubMed Web of Science ®Google Scholar
• Baskerville TA, Douglas AJ. Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders. CNS Neurosci Ther. 2010;16:e92–123.
   PubMed Web of Science ®Google Scholar
• Baskerville TA, Allard J, Wayman C, et al. Dopamine-oxytocin interactions in penile erection. Eur J Neurosci. 2009;30:2151–2164.
   PubMed Web of Science ®Google Scholar
• Burnstock G. Purinergic cotransmission. Exp Physiol. 2009;94:20–24.
   PubMed Web of Science ®Google Scholar
• Soloff MS, Hinko A. Oxytocin receptors and prostaglandin release in rabbit amnion. Ann N Y Acad Sci. 1993;689:207–218.
   PubMed Web of Science ®Google Scholar
• Masunaga K, Yoshida M, Inadome A, et al. Prostaglandin E2 release from isolated bladder strips in rats with spinal cord injury. Int J Urol. 2006;13:271–276.
   PubMed Web of Science ®Google Scholar
• Takeda H, Yamazaki Y, Igawa Y, et al. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn. 2002;21:558–565.
   PubMed Web of Science ®Google Scholar
• Kim JC, Park EY, Seo SI, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006;175:1773–1776. discussion 6.
   PubMed Web of Science ®Google Scholar
• Ishizuka O, Mattiasson A, Andersson KE. Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J Urol. 1995;153:2034–2038.
   PubMed Web of Science ®Google Scholar
• Erickson DR, Propert KJ. Pregnancy and interstitial cystitis/painful bladder syndrome. Urol Clin North Am. 2007;34:61–69.
   PubMed Web of Science ®Google Scholar
• Battin DA, Marrs RP, Fleiss PM, et al. Effect of suckling on serum prolactin, luteinizing hormone, follicle-stimulating hormone, and estradiol during prolonged lactation. Obstet Gynecol. 1985;65:785–788.
   PubMed Web of Science ®Google Scholar
• Stricker R, Eberhart R, Chevailler MC, et al. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med. 2006;44:883–887.
   PubMed Web of Science ®Google Scholar
• Schneider T, Marschall-Kehrel D, Hanisch JU, et al. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010;64:1287–1293.
   PubMed Web of Science ®Google Scholar
• Lucero J, Harlow BL, Barbieri RL, et al. Early follicular phase hormone levels in relation to patterns of alcohol, tobacco, and coffee use. Fertil Steril. 2001;76:723–729.
   PubMed Web of Science ®Google Scholar
• Lim MM, Young LJ. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm Behav. 2006;50:506–517.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Thomas CA, Hayashi Y, et al. The overactive bladder: epidemiology and morbidity. Urol Clin North Am. 2006;33:433–438.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Kuzina I, Kuznetsov V, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male. 2018;21:121–129.
   PubMed Web of Science ®Google Scholar